Everything Herbal - Main Page - PS-Survival.com

Specific Vitamins, Herbs, Medications
hypericum extract LI 160. J Geriatr Psychiatry Neurol. 1994;7(suppl
1):S15–S18. 20. Laakmann G, Schüle C, Baghai T, et al. St. John's
wort in mild to moderate depression: the relevance of hyperforin for the
clinical efficacy. Pharmacopsychiatry. 1998;31(suppl):54–59. 21.
Schrader E, Meier B, Brattstrom A. Hypericum treatment of mild-moderate
depression in a placebo-controlled study. A prospective, double-blind,
randomized, placebo-controlled, multicentre study. Hum Psychopharmacol.
1998;13:163–169. 22. Linde K, Ramirez G, Mulrow CD, et al. St. John's
wort for depression—An overview and meta-analysis of randomised
clinical trials.
BMJ. 1996;313:253–258. 23. Ernst E. St. John's wort, an
anti-depressant? A systematic, criteria-based review. Phytomedicine.
1995;2:67–71. 24. Schrader E. Equivalence of St John's wort extract (Ze
117) and fluoxetine: a randomized, controlled study in mild–moderate
depression. Int Clin Psychopharmacol. 2000;15:61–68. 25. Harrer G,
Schmidt U, Kuhn U, et al. Comparison of equivalence between the St. John's
wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung.
1999;49:289–296. 26. Brenner R, Azbel V, Madhusoodanan S, et al.
Comparison of an extract of hypericum (LI 160) and sertraline in the
treatment of depression: a double-blind, randomized pilot study. Clin Ther.
2000;22:411–419. 27. Philipp M, Kohnen R, Hiller KO. Hypericum extract
versus imipramine or placebo in patients with moderate depression: randomised
multicentre study of treatment for eight weeks. BMJ.
1999;319:1534–1539. 28. Vorbach EU, Arnoldt KH, Hubner WD. Efficacy
and tolerability of St. John's w
ort extract LI 160 versus imipramine in patients with severe depressive
episodes according to ICD-10. Pharmacopsychiatry. 1997;30(suppl
2):81–85. 29. Schulz V, Hansel R, Tyler VE. Rational Phytotherapy:
A Physicians' Guide to Herbal Medicine. 3rd ed. Berlin, Germany:
Springer-Verlag; 1998:59. 30. Linde K, Ramirez G, Mulrow CD, et al. St.
John's wort for depression—An overview and meta-analysis of randomised
clinical trials. BMJ. 1996;313:253–258. 31. Ernst E. St. John's wort,
an anti-depressant? A systematic, criteria-based review. Phytomedicine.
1995;2:67–71. 32. Martinez B, Kasper S, Ruhrmann S, et al. Hypericum in
the treatment of seasonal affective disorders. J Geriatr Psychiatr Neurol.
1994;7(suppl 1):S29–S33. 33. Schrader E. Equivalence of St John's wort
extract (Ze 117) and fluoxetine: a randomized, controlled study in
mild-moderate depression. Int Clin Psychopharmacol. 2000;15:61–68. 34.
Woelk H. Comparison of St John's wort and imipramine for treating depression:
randomised controlled trial. BMJ. 2000;321:536–539. 35. Woelk H,
Burkard G, Grunwald J. Benefits and risks of the hypericum extract LI 160:
Drug monitoring study with 3,250 patients. J Geriatr Psychiatr Neurol.
1994;7(suppl 1):S34–S38. 36. De Smet PA, Nolen WA. St. John's wort as
an anti-depressant. BMJ. 1996;3:241–242. 37. Schulz V, Hansel R, Tyler
VE. Rational Phytotherapy: A Physicians' Guide to Herbal Medicine. 3rd ed.
Berlin, Germany: Springer-Verlag; 1998:56. 38. Seigers CP, Biel S, Wilhelm
KP. Phototoxicity caused by hypericum [translated from German].
Nervenhielkunde. 1993;12:320–322. 39. Brockmoller J, Reum T, Bauer S,
et al. Hypericin and pseudohypericin: Pharmacokinetics and effects on
photosensitivity in humans. Pharmacopsychiatry. 1997;30(suppl
2):94–101. 40. Mirossay A, Mirossay L, Tothova J, et al.
Potentiation of hypericin and hypocrellin-induced phototoxicity by
omeprazole. Phytomedicine. 1999;6:311–317. 41. Roberts J Presentation
at the 1999 Meeting of t
he American Society for Photobiology. 42. Ondrizek RR, Chan PJ, Patton WC, et
al. An alternative medicine study of herbal effects on the penetration of
zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid.
Fertil Steril. 1999;71:517–522. 43. Suzuki O, Katsumata Y, Oya M, et
al. Inhibition of monoamine oxidase by hypericin. Planta Med.
1984;50:272–274. 44. Bladt S, Wagner H. Inhibition of MAO by
fractions and constituents of hypericum extract. J Geriatr Psychiatr Neurol.
1994;7(suppl 1):S57–S59. 45. Thiede HM, Walper A. Inhibition of MAO and
COMT by hypericum extracts and hypericin. J Geriatr Psychiatr Neurol.
1994;7(suppl 1):S54–S56. 46. DeMott K. St. John's wort tied to
serotonin syndrome. Clinical Psychiatry News. 1998;26:28. 47 Gordon JB.
SSRIs and St. John's wort: Possible toxicity? Am Fam Physician. 1998;57:950,
953. 48. Lantz MS, Buchalter E, Giambanco V. St. John's wort and
antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol.
1999
;12:7–10. 49. Mason BJ, Blackburn KH. Possible serotonin syndrome
associated with tramadol and sertraline coadministration. Ann Pharmacother.
1997;31:175–177. 50. Hernandez AF, Montero MN, Pla A, et al. Fatal
moclobemide overdose or death caused by serotonin syndrome? J Forensic Sci.
1995;40:128–130. 51. Jobst KA, McIntyre M, St. George D, et al. Safety
of St John's wort (Hypericum perforatum). Lancet. 2000,355:575. 52.
Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St
John's wort. Lancet. 2000;355:548. 53. Ruschitzka F, Meier PJ, Turina M, et
http://www.herbnet.com/ask%20the%20herbalist/asktheherbalist_questions%20on%20specifics.htm (30 of 46) [5/17/2004 9:08:18 AM]